update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
Published 6 months ago • 66 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:34
follow-up from the commands trial beyond the primary endpoint: luspatercept versus esa-based therapy
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:43:48
speciality update with hematologists
-
34:33
patch that app up (by using installomator) | jnuc 2023
-
3:28
preclinical studies of tasquinimod in mds: in vitro and in vivo investigations
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
1:15
luspatercept for the treatment of patients with lower-risk mds and esa failure
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
1:58
canakinumab plus darbepoetin in patients with lr-mds following esa failure
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
1:47
the commands study: luspatercept versus epoetin alfa for esa-naïve lower-risk mds-associated anemia
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml